SCHEMBL14501802

SCHEMBL14501802

CN(C)C1CCN(c2ccc(NC(=O)c3ccc(N4CCOCC4)cc3)cc2)C1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 9/20 0.74
MAPT P10636 5/20 0.65
RAB9A P51151 2/20 0.65
ATM Q13315 1/20 0.65
NPC1 O15118 1/20 0.65
TP53 P04637 1/20 0.65
PKM P14618 1/20 0.65
MAPK1 P28482 1/20 0.65
HDAC8 Q9BY41 1/20 0.62
HDAC6 Q9UBN7 1/20 0.62
LMNA P02545 2/20 0.62
ALDH1A1 P00352 1/20 0.61
HTR1B P28222 1/20 0.58
KDM1A O60341 2/20 0.57
MAOA P21397 2/20 0.57
MAOB P27338 2/20 0.57
KDM1B Q8NB78 2/20 0.57
RCOR1 Q9UKL0 2/20 0.57
HTT P42858 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12530444 0.90 MCHR1 (0.76) MCHR1MAPTRAB9ANPC1LMNA
SCHEMBL12530925 0.89 MCHR1 (0.69) MCHR1MAPTRAB9AATMNPC1
SCHEMBL12530893 0.88 MCHR1 (0.78) MCHR1MAPTRAB9ANPC1TP53
SCHEMBL12529830 0.88 MCHR1 (0.89) MCHR1RAB9ANPC1
SCHEMBL12529621 0.88 MCHR1 (0.89) MCHR1MAPTRAB9ANPC1TP53
SCHEMBL1750361 0.88 MCHR1 (0.81) MCHR1
SCHEMBL1750252 0.88 MCHR1 (0.78) MCHR1MAPTRAB9ANPC1LMNA
SCHEMBL1750121 0.87 MCHR1 (0.76) MCHR1
SCHEMBL12530860 0.87 MCHR1 (0.76) MCHR1RAB9ANPC1TP53MAPK1
SCHEMBL1749572 0.87 MCHR1 (0.76) MCHR1PKMLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7223788-B2 therapy for eating disorders, anorexigenic agents, antidiabetic agents, reducing weight in mammals, circadian rhythm disease, psychological disorders SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-05-29 US disclosed
US-7223788-B2 therapy for eating disorders, anorexigenic agents, antidiabetic agents, reducing weight in mammals, circadian rhythm disease, psychological disorders SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-05-29 US disclosed